An Evaluation of Perceptions and Quality of Life Among Patients Receiving Ipilimumab for Melanoma

Protocol
11-184
Full Title
Ipilimumab Treatment Kinetics: An Evaluation of Patient Perceptions and Quality of Life
Purpose

Ipilimumab is a drug that was approved in 2011 for the treatment of advanced melanoma. It works by allowing the immune system to fight cancer cells. To date, the perspectives of patients being treated with immunologically based therapies have not been thoroughly evaluated. Understanding patients’ perceptions of ipilimumab therapy and their quality of life during treatment can help doctors better comprehend the experiences of patients receiving ipilimumab.

In this study, researchers will survey patients (via interviews and questionnaires) about their perceptions of ipilimumab therapy before, during, and after treatment, and also ask them about their quality of life.

Eligibility

Participants in this study include English-speaking adults (age 18 and older) who will be receiving ipilimumab as part of their treatment for advanced melanoma.

For more information about this study, please contact Dr. Jennifer Hay at 646-888-0039.

Disease(s)
Melanoma
Quality of Life
Locations
Related Diseases